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Abstract
Purpose To report the early results of suprachoroidal
silicone implant surgery in intractable glaucoma.
Materials and methods A modified silicone implant with
no valve was implanted into the suprachoroidal space of 15
eyes with intractable glaucoma.
Results The mean age of the patients was 53.0 ± 24.5
(range 7–85) years, the mean follow-up time was
17.1 ± 4.8 (range 10–28) months, and the mean preoper-
ative intraocular pressure (IOP) of patients receiving two or
more medications was 33.1 ± 9.8 mmHg. At the last fol-
low-up visit, mean IOP was 16.5 ± 7.9 (range 10–35)
mmHg (Wilcoxon signed rank test, p = 0.001). The
functional success, i.e., IOP B21 mmHg both with and
without antiglaucomatous drugs, was 93.3%. The total
success rate, i.e., IOP B21 mmHg without medication, was
13.3%. The average number of antiglaucomatous drugs
used was 3.8 (range 2–5) preoperatively, and 2.2 postop-
eratively (range 0–4) (Wilcoxon signed rank test,
p = 0.011). There was a C30% decrease in the IOP of
66.6% of the eyes. Shallow choroidal detachment as proof
of drainage was evident in all cases.
Conclusion Drainage of the aqueous humor from the
anterior chamber to the suprachoroidal space via implan-
tation of a modified silicone implant is effective in low-
ering the IOP in intractable glaucoma.
Keywords Complications  Glaucoma  Glaucoma
drainage device  Intraocular pressure  Suprachoroidal
implant
Introduction
Despite the high incidence of surgical failure due to cica-
trization, filtering surgery with adjunctive antimetabolite
therapy might increase the outcome of intractable glau-
coma in some cases [1–3]. However, antimetabolite ther-
apy is associated with a large number of postoperative
complications, and filtering surgery with adjunctive anti-
metabolite therapy is not always successful. An alternative
method which facilitates aqueous drainage is a glaucoma
shunt implantation to provide a passage from the anterior
chamber to the subconjunctival space. Although the
implantation of such a shunt is a complex procedure with
numerous pre- and postoperative complications, the suc-
cess rate for glaucoma shunts in intractable glaucoma has
been reported to be [50% in most series [1], with sub-
conjunctival fibrosis reported as the most common cause of
failure [4]. The results that have been reported after inci-
sional needling and excisional revision of the subcon-
junctival adhesion at the filtration site are disappointing.
The virtual space between the external surface of the
choroid and the internal surface of the sclera does not
clinically manifest under physiological conditions. How-
ever, this suprachoroidal space is reported to be used to
achieve glaucoma shunting in eyes with cicatrized con-
junctiva [1, 5].
In this retrospective study, we report the short-term
results of suprachoroid silicone implants in 15 eyes with
intractable glaucoma.
Materials and methods
Fifteen eyes of 14 patients (9 women, 5 men) who
had undergone suprachoroidal shunt implantation for
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intractable glaucoma after previous glaucoma surgical
procedures between July 2007 and June 2009 were enrolled
in the study. Preoperative diagnosis was open angle glau-
coma in seven eyes, secondary glaucoma due to trauma in
four eyes and juvenile glaucoma in four eyes. The inclu-
sion criteria were the presence of at least one prior
unsuccessful glaucoma surgery and advanced glaucoma. A
suprachoroidal drainage shunt was implanted in all eyes to
control intraocular pressure (IOP).
The anterior chamber angles were evaluated at the first
visit using a Goldmann three-mirror lens. At baseline and on
each subsequent examination, an anterior and posterior
segment evaluation by slit-lamp and specular microscopy
was performed. A Goldmann applanation tonometer was
used to measure the IOP at each visit. The mean follow-up
time was 17.1 ± 4.8 (range 10–28) months. Functional
success was defined as an IOP of B21 mmHg both with and
without antiglaucomatous medication at postoperative
month 6. Total success was defined as an IOP of B21 mmHg
without antiglaucomatous medication at postoperative
month 6. Any IOP result[21 mmHg was considered to be a
failure, and an IOP\5 mmHg was classified as hypotony.
All surgery, except on children (general anesthesia), was
performed under topical anesthesia by the same surgeon (HA).
A silicone tube (internal diameter 0.3 mm, external diameter
0.6 mm) with beveled edges was implanted in all eyes.
As described by Jordan et al. [5], we first made a fornix-
based conjunctival flap, then prepared 4 9 4-mm superfi-
cial and 3 9 3-mm deep posterior limbus-based scleral
flaps (Fig. 1). Unlike the surgical approach employed by
Jordan et al. [5], which was always in the inferior quadrant,
we chose the healthiest conjunctival area, rather than any
one specific area, for the surgical approach, and our scleral
flap was not triangular but rectangular. A small incision
was made on the sclera to access the suprachoroidal space.
A deep scleral flap was created to visualize the supracho-
roidal space access without causing choroidal injuries.
Viscoelastics were used both to protect the anterior
chamber from mechanical trauma and to dissect the su-
prachoroidal space. A 23-gauge needle was inserted
through the limbus to the anterior chamber, and the silicone
tube was pushed to the anterior chamber from one side
through the suprachoroidal space. The length of all the
tubes placed in the suprachoroidal space was 2 mm. The
silicone tube was stabilized with a single 10.0 nylon suture
(Fig. 2a, b); the scleral flaps were sutured with 10.0 nylon,
and the conjunctiva was sutured with 8.0 vicryl sutures. No
antimetabolite agent was used.
Topical corticosteroids and antibiotics were prescribed
four times daily for the first postoperative month. The
patients were examined at postoperative weeks 1 and 4 and
at 1-month intervals thereafter. This study was approved by
Fig. 1 The position of the implanted beveled edged silicon tube.
Note that the suprachoroid part is approximately 2 mm
Fig. 2 a Silicone tube
introduced to both the anterior
chamber and suprachoroidal
space, b silicone tube in the
anterior chamber
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our Institutional Review Board (IRB) and complies with
the Declaration of Helsinki. The results are reported as the
mean ± standard error (SE). The Wilcoxon signed rank test
was used for statistical evaluation, and a p value\0.05 was
considered to be significant.
Results
The demographic data and preoperative clinical charac-
teristics of 15 eyes of 14 patients who were enrolled are
presented in Table 1. The mean age of the patients was
53.0 ± 24.5 (range 7–85) years. All enrolled eyes had
undergone numerous glaucoma surgical procedures
(1.9 ± 1.0, range 1–4). Placement of the modified silicone
implant to the suprachoroidal space was achieved in all
cases.
Mean preoperative IOP of the patients receiving two or
more medications was 33.1 ± 9.8 mmHg. At the last fol-
low-up visit, the mean IOP was 16.5 ± 7.9 (range 10–35)
mmHg (Fig. 3). The difference between pre- and postop-
erative IOP was statistically significant (Wilcoxon signed
rank test, p = 0.001). The functional success rate was
93.3%, whereas the total success rate was 13.3%. A C30%
decrease in IOP was detected in 66.6% of the eyes.
The average number of antiglaucomatous drug used pre-
and postoperatively was 3.8 (range 2–5) and 2.4 (range
0–4), respectively (Wilcoxon signed rank test, p = 0.011).
Shallow choroidal detachment as proof of drainage was
evident on B-mode ultrasonography images in all cases
throughout the follow-up period. No resistant postoperative
hypotony or IOP spikes were encountered. None of the
eyes developed any complications, such as shallow anterior
chamber, corneal edema, tube migration to anterior
chamber, hyphema, suprachoroidal hemorrhage, retinal
detachment, phthisis bulbi or endophthalmitis, which can
occur with this kind of surgery. No bleb or conjunctival
leaks were detected during the follow-up period.
The pre- and postoperative corneal endothelial cell
count was 590.45 ± 26.34 and 587 ± 19.23, respectively,
and the difference was not statistically significant (Wilco-
xon signed rank test, p = 0.21).
The suprachoroidal drainage implant surgery is efficient
as a means of IOP reduction, antiglaucomatous drug
number reduction, and functional success rate (Table 1).
Overall, the technique was safe with only minor compli-
cations, but no visual acuity loss or corneal endothelial
damage.
Discussion
The aqueous humor can leave the eye via one of two
routes: (1) through the trabecular meshwork into the
Schlemm channel and then into the intrascleral and epi-
scleral venous plexus; (2) through a second pathway that
originates with the passage of the aqueous humor through
the uveoscleral route. The aqueous humor flows along the
interstitial tissue of the ciliary muscle into the supracho-
roidal space and out through the sclera or through the
vascular channels of the sclera into the connective tissue
of the orbit [6]. Bill et al. [7] demonstrated that the
uveoscleral outflow accounts for \20% of the total
drainage of aqueous humor in human eyes. However,
recent studies show a much higher role for the contribution
of uveoscleral outflow in the total drainage of aqueous
humor. Toris et al. [8] report that the uveoscleral outflow
accounts for 54% of the total outflow in young healthy
humans.
The suprachoroidal space is the virtual space between
the external surface of the choroid and the internal surface
of the sclera. Under physiological conditions, this space
does not manifest clinically. The uveoscleral outflow can
be influenced directly both surgically and pharmacologi-
cally (e.g. with latanoprost) [9]. The classic transscleral
form of cyclodialysis was first described by Leopold Heine
in 1905 as a novel surgical treatment for glaucoma and was
the first surgical approach to exploit the resorptive IOP-
lowering capacity of the choroid [1].
In 1973, Portney [10] reported five eyes with intractable
glaucoma that had undergone cyclodialysis in combination
with implantation of a T-shaped silicone elastomer to keep
the ciliary body detached from the sclera and for permanent
connection of the anterior chamber to the suprachoroidal
space. However, the surgery failed in all the eyes. The
results of histological testing on the ultimately enucleated
eyes revealed that the presence of inflammatory cells and
fibrous scar formation only a few weeks after the initial
surgery had caused failing of the internal fistula. Scarring
Fig. 3 Baseline intraocular pressure (IOP) and change in IOP of the
patients over time (mean ± standard error)
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in the suprachoroidal space was probably the main factor
hindering long-term success.
Ozdamar and colleagues [11] implanted a modified
Krupin valve, which is usually designed for episcleral
fixation, into the suprachoroidal space in four blind human
eyes. They reported a clinical IOP-lowering success rate of
75% (IOP \21 mmHg, no medications). There were no
severe postoperative complications, and they found no
histopathological findings related to fibrous encapsulation
of the valve.
Another antiglaucomatous implant procedure for su-
prachoroidal drainage has been described by Yablonski
[12]. This author enrolled 23 eyes in a clinical trial, of
which only three had undergone previous incisional glau-
coma surgery. After a mean of 324 ± 136 days, 18 eyes
required laser suture-lysis of the scleral nylon sutures or
postoperative 5-fluorouracil to control the IOP. A signifi-
cant drop in IOP from a preoperative value of 25.4 to a
postoperative value of 13.8 mmHg and a significant
decrease in the need for topical antiglaucoma medication
(preoperative 3.0, postoperative 1.1) were noted.
An approach using a tube implant for suprachoroidal
drainage has been described by Jordan and coworkers [5].
Thirty-one eyes with intractable glaucoma that had
undergone multiple previous filtration and/or cyclodes-
tructive procedures (mean 3.5 ± 1.9) were included in this
prospective case series. They performed the surgery at the
inferior conjunctival area, which has appeared to be less
traumatized in previous surgeries. The authors reported a
success rate of 70% after 30 weeks, 60% after 1 year and
40% after 76 weeks. The mean functional survival time of
the implanted silicone tube was 56 weeks. No serious cases
of postoperative bleeding, hypotony or infection were
noted. The first failure peak was observed after only
4 weeks, and the second after 1 year. Ultrasound biomi-
croscopy revealed that fibrous obstruction of the posterior
lumen of the silicone tube in all failed eyes was the cause
of the failure.
A new device for suprachoroidal drainage is the Gold
Micro Shunt (GMS; SOLX, Waltham, MA), which is made
of biocompatible, 99.95% 24-carat gold [1]. The GMS can
be implanted by making either a special corneal incision or
a scleral incision at a distance of 2.5 mm from the limbus,
inserting the GMS first anteriorly into the anterior chamber
and then posteriorly into the suprachoroidal space. Mela-
med and colleagues reported a case series of 38 eyes with
an 11.7-month follow-up [13]. They observed a mean IOP
decrease of 9 mmHg (from 27.6 to 18.2 mmHg;
p \ 0.001). Surgical success was achieved in 30 patients
(79%) (IOP [5 and \22 mmHg, both with and without
antiglaucoma medication). Eight patients had mild to
moderate transient hyphema.
In our series, the suprachoroid implant surgery was
successful in controlling glaucoma in 66.6% of eyes over a
mean follow-up period of 17.1 ± 4.8 (range 10–28)
months, which is similar to success rates reported in other
studies [5, 11]. Unlike filtrating surgeries, the goal in this
type of surgery is not to achieve subconjunctival filtration;
therefore, conjunctival scarring does not affect the opera-
tion success rate as much as it affects that of filtrating



















1 28 M SG 20/40 20/40 38 10 5 4 TE (91), GDD (91)
2 34 F SG 20/500 20/500 53 10 5 2 TE (92)
3 73 M POAG 20/500 20/800 40 12 5 3 TE (93)
4 25 F JG 20/1250 20/320 42 14 3 4 GDD (91)
5 80 F POAG 20/1250 20/1250 25 23 3 4 NPGS (91)
6 57 M JG 20/40 20/28.5 30 10 3 1 GDD (91)
6 57 M JG 20/25 20/20 30 10 4 1 GDD (91)
7 59 M SG 20/100 20/66.6 30 10 4 3 TE (92)
8 63 F POAG 20/25 20/20 20 16 3 4 TE (91)
9 56 F POAG 20/1250 20/1250 40 12 2 4 TE (94)
10 7 F SG 20/200 20/200 38 10 4 3 TE (92), GDD (91)
11 78 F POAG 20/400 20/50 22 10 3 1 TE (91)
12 19 F JG 20/200 20/400 44 10 4 3 TE (92), GDD (91)
13 85 F POAG 20/100 20/400 25 10 4 0 TE (93)
14 74 M POAG 20/100 20/200 21 10 5 0 NPGS (91)
F, Female, M male, BCVA best corrected visual acuity,SG secondary glaucoma, POAG primary open angle glaucoma, JG juvenile glaucoma, TE
trabeculectomy, GDD glaucoma drainage device, NPGS non-penetrating glaucoma surgery
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surgeries. As all of our eyes had undergone at least one
(range 1–4) glaucoma surgery, this success rate is compa-
rable with that of the previously reported studies [5, 11,
12]. Although Melamed et al. report a higher success rate
(79%) using GMS, this device is expensive, especially for
less developed countries [13]. As reported by Jordan et al.
[5], we noticed a tendency in the IOP to increase in the
postoperative week 4, probably due to scar formation [5].
To overcome this IOP rise, we added antiglaucomatous
medication to the therapeutic regimen, achieving a success
rate of 93.3% of eyes. We did not come across any mild or
severe complications in any of our cases with this cheap
and practical equipment [5, 11, 13]. We also did not detect
any significant decreases in the best corrected visual acuity
due to tube implantation. Although our follow-up time was
relatively short, the success rate of this technique for
suprachoroid implant surgery in intractable glaucoma
seems to be promising.
In conclusion, we have shown that suprachoroid implant
surgery can effectively control IOP in eyes with intractable
glaucoma. However, the long-term benefit of the newer and
partially promising antiglaucomatous suprachoroid implants
that improve uveoscleral outflow still has to be proven in
prospective randomized multicenter trials.
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